3-(2-{2-[2-({[2'-(Isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-propionic acid | 929087-88-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-{2-[2-({[2'-(Isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-propionic acid
• CAS: 929087-88-7
• 化学式: C₃₁H₃₆N₄O₁₁S
• 分子量: 672.713
• InChiKey: UXEZMCSGFZADJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  47.0
• 可旋转键数：
  21.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  192.76
• 氢给体数：
  2.0
• 氢受体数：
  12.0

反应信息

• 作为反应物：
  描述：

  3-(2-{2-[2-({[2'-(Isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-propionic acid 在 对甲苯磺酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 丙酮 作用下， 以 二氯甲烷 为溶剂， 生成 N-[4-(3,5-Dioxo-hexyl)-phenyl]-3-(2-{2-[2-({[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-propionamide
  参考文献：
  名称：

  Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies™

  摘要：

  Aryl sulfonamide-based endothelin antagonists were synthesized and covalently linked to the reactive lysine of the m38C2 antibody to create a series of CovX-Bodies. These chemically programmed antibodies behaved as potent endothelin receptor antagonists in vitro and had antitumor efficacy in a prostate cancer xenograft model which, on a molar basis, far exceeded the activity of the parent small molecule. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.009
• 作为产物：
  描述：

  17,17-Dimethyl-15-oxo-3,6,9,12,16-pentaoxaoctadecanoic acid 在 盐酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-(2-{2-[2-({[2'-(Isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-propionic acid
  参考文献：
  名称：

  Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies™

  摘要：

  Aryl sulfonamide-based endothelin antagonists were synthesized and covalently linked to the reactive lysine of the m38C2 antibody to create a series of CovX-Bodies. These chemically programmed antibodies behaved as potent endothelin receptor antagonists in vitro and had antitumor efficacy in a prostate cancer xenograft model which, on a molar basis, far exceeded the activity of the parent small molecule. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.009